I agree misiu! I just posted a similar response on ihub. I know there will be competition for mono, but combo competition is very limited and thus likely the reason leronlimab was even pursued by CytoDyn back several years ago (along with the stellar safety profile).

I don't see anyway the share price doesn't appreciate significantly if only based on combo.....hopefully other indications will also add value and we don't have to wait until revenue is in the bank, but if that is the case so be it......the market can only deny the facts for so long before the revenue received makes it a fact rather than a conservative projection.